Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Koeppen

Showing results (31-40 of 147) with videos related to

Pageof 15
Sort By:
Cancer Research|October 20, 2004
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomasDavid Dornan, Sheila Bheddah, Kim Newton, et al.
Cancer Research|February 12, 2004
EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancerWeiguang Mao, Elizabeth Luis, Sarajane Ross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
EphB2 is a prognostic factor in colorectal cancerAdrian M Jubb, Fiona Zhong, Sheila Bheddah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic miceDavid Finkle, Zhi Ricky Quan, Vida Asghari, et al.
Human Pathology|May 19, 2007
Epidermal growth factor receptor in osteosarcoma: expression and mutational analysisYong Hannah Wen, Hartmut Koeppen, Roberto Garcia, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 18, 2010
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous diseaseArmen Kasyan, L Jeffrey Medeiros, Zhuang Zuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survivalHongkui Jin, Renhui Yang, Jed Ross, et al.
Oncotarget|June 10, 2011
p21-activated kinase 1: PAK'ed with potentialChristy C Ong, Adrian M Jubb, Wei Zhou, et al.
Oral Oncology|March 30, 2017
Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancerOscar Siu Hong Chan, Marcin Kowanetz, Wai Tong Ng, et al.
International Immunology|July 20, 2006
Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemiaAndrew G Polson, Bing Zheng, Kristi Elkins, et al.
Pageof 15

Showing results (31-40 of 147) with videos related to

Sort By:
Pageof 15
Cancer Research|October 20, 2004
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomasDavid Dornan, Sheila Bheddah, Kim Newton, et al.
Cancer Research|February 12, 2004
EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancerWeiguang Mao, Elizabeth Luis, Sarajane Ross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
EphB2 is a prognostic factor in colorectal cancerAdrian M Jubb, Fiona Zhong, Sheila Bheddah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic miceDavid Finkle, Zhi Ricky Quan, Vida Asghari, et al.
Human Pathology|May 19, 2007
Epidermal growth factor receptor in osteosarcoma: expression and mutational analysisYong Hannah Wen, Hartmut Koeppen, Roberto Garcia, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 18, 2010
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous diseaseArmen Kasyan, L Jeffrey Medeiros, Zhuang Zuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survivalHongkui Jin, Renhui Yang, Jed Ross, et al.
Oncotarget|June 10, 2011
p21-activated kinase 1: PAK'ed with potentialChristy C Ong, Adrian M Jubb, Wei Zhou, et al.
Oral Oncology|March 30, 2017
Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancerOscar Siu Hong Chan, Marcin Kowanetz, Wai Tong Ng, et al.
International Immunology|July 20, 2006
Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemiaAndrew G Polson, Bing Zheng, Kristi Elkins, et al.
Pageof 15